参考文献/References:
[1]王建旗,史旭波,马长生,等.炎症预测和预防动脉粥样硬化性心血管事件的研究进展[J].心血管病学进展,2018,39(5):687-690.
[2] Liu ZX, Ji HH, Yao MP, et al. Serum Metrnl is associated with the presence and severity of coronary artery disease[J].J C ell M ol M ed, 2019,23(1):271-280.
[3]Yang Z, Shi L, Xue Y, et al. Interleukin-32 increases in coronary arteries and plasma from patients with coronary artery disease[J]. Clin Chim A cta,2019,497:104-109.
[4]Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future[J].I mmunity, 2013,39(6):1003-1008.
[5]Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family[J]. Annu Rev Immunol, 2009,27:519-550.
[6]Khan R, Rheaume E, Tardif JC. Examining the role of and treatment directed at IL-1β in atherosclerosis[J].Curr Atheroscler R ep,2018,20(11):53.
[7]Dhorepatil A, Ball S, Ghosh RK, et al. Canakinumab:promises and future in cardiometabolic diseases and malignancy[J].Am J Trop M ed H yg,2019,132(3):312-324.
[8]Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with in terleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor[J]. Eur J Clin I nvest,1996,97(3):769-776.
[9]Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice[J].Arterioscl Throm Vas,2003,23(4):656-660.
[10]张源明,钟良军,何秉贤,等.白介素1B启动子区域-511位点C/T基因多态性与冠心病严重程度的相关性[J].中华医学遗传学杂志,2006,23(1):86-88.
[11] Chen X, Chen X, Xu Y, et al. Association of six CpG-SNPs in the inflammation-related genes with coronary heart disease[J].Hum G enomics,2016,10(suppl 2 ):21.
[12]Rios DL, Cerqueira CC, Bonfim-Silva R, et al. Interleukin-1 beta and interleukin-6 gene polymorphism associations with angiographically assessed coronary artery disea se in Brazilians[J].Cytokine,2010,50(3):292-296.
[13]Zhou L, Cai J, Liu G, et al. Associations between interleukin-1 gene polymorphisms and coronary heart disease risk: a meta-analysis[J]. Pols O ne,2012,7(9):e45641.
[14]Tabrez S, Jabir NR, Firoz CK, et al. Estimation of interleukin-1β promoter (-31 C/T and -511 T/C) polymorphisms and its level in coronary artery disease patients[J].J Cell B iochem,2017,118(9):2977-2982.
[15]杨恩月,金光,金贞玉,等.白细胞介素-1β基因rs1143627与冠心病的相关性[J].中国老年学杂志,2018,38(11):2590-2591.
[16]Sreekanth MS, Esdan Basha SK, Arun Kumar G, et al. Association of IL-1β +3953 C and HLA-DRB1*15 with coronary artery and rheumatic heart diseases in South India[J].Hum I mmunol,2016,77(12):1275-1279.
[17]Hall SK, Perregaux DG, Gabel CA, et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of interleukin-1 beta protein[J].Arthritis Rheum,2004,50(6):1976-1983.
[18]Berger P, McConnell JP, Nunn M, et al. C-reactive protein levels are influenced by common IL-1 gene variations[J].Cytokine,2002,17(4):171-174.
[19]Li L, Li E, Zhang LH, et al. IL-6-174G/C and IL-6-572C/G polymorphisms are associated with increased risk of coronary artery disease[J].Genet Mol Res,2015,14(3):8451-8457.
[20]刘世林,黄文军,闫博宇.Homer1、IL-1β、RBP4、TNF-α及LKB1在冠心病中的表达及意义[J].广东医学,2019,40(3):399-402.
[21]Patti G, D’Ambrosio A, Dobrina A, et al. Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease[J].J Thromb Thrombolysis,2002,14:139 -143.
[22]Patti G, Di Sciascio G, D’Ambrosio A, et al. Prognostic value of interleukin-1 receptor antagonist in patients undergoing percutaneous coronary intervention[J].Am J Cardiol,2002,89:372 -376.
[23]Schofer N, Ludwig S, Rübsamen N, et al. Prognostic impact of Interleukin-1 receptor antagonist in patients with documented coronary artery disease[J]. Int J Cardiol,2018,257:24 -29.
[24]Correia LC, Andrade BB, Borges VM, et al. Prognostic value of cytokines and chemokines in addition to the GRACE Score in non-ST-elevation acute coronary syndromes[J].Clin Chim Acta,2010,411( 7-8):540-545.
[25]?rn S,Ueland T,Manhenke C, et al. Increased interleukin-1β levels are associated with left ventricular hypertrophy and remodelling following acute ST segment elevation myocardial infarction treated by primary percutaneous coronary intervention[J].J Intern Med,2012,272(3): 267-276.
[26]Prondzinsky R, Unverzagt S, Lemm H, et al. Interleukin-6, -7, -8 and -10 predict outcome in acute myocardial infarcti on complicated by cardiogenic shock[J]. Clin Res Cardiol,2012,101(5):375-384.
[27]Abbate A, Kontos MC, Abouzaki NA, et al. Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)[J].Am J Cardiol,2015,115(3):288 -292.
[28]Choudhury RP, Birks JS, Mani V, et al. Arterial effects of canakinumab in patientswith atherosclerosis and type?2diabetes or glucose intolerance[J].J Am Coll C ardiol,2016,68(16):1769-1780.
[29]Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease[J].New Engl J M ed,2017,377(12):1119-1131.
[30]Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive p rotein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial [J].Lancet(London, England),2018,391(10118):319-328.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(2):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(2):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(2):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(2):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]胥雪莲,何川.炎症与动脉粥样硬化[J].心血管病学进展,2015,(5):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
XU Xuelian,HE Chuan.Inflammation and Atherosclerosis[J].Advances in Cardiovascular Diseases,2015,(2):634.[doi:10.3969/j.issn.1004-3934.2015.05.029]
[9]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(2):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[10]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[11]焦新峰 刘正霞 鲁翔.白介素-8在冠心病中的研究进展[J].心血管病学进展,2019,(8):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
JIAO Xinfeng,LIU Zhengxia,LU Xiang.Research Progress of Interleukin-8 in Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(2):1126.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.014]
[12]王丁坤 李卫萍.正五聚蛋白3在冠心病中的研究进展[J].心血管病学进展,2021,(11):968.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]
WANG Dingkun,LI Weiping.Pentraxin 3 in Coronary Atherosclerotic Heart Disease[J].Advances in Cardiovascular Diseases,2021,(2):968.[doi:10.16806/j.cnki.issn.1004-3934.2021.11.000]